PFE Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Pfizer Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$50.11|
|52 Week High||US$61.71|
|52 Week Low||US$40.94|
|1 Month Change||-3.24%|
|3 Month Change||0.38%|
|1 Year Change||3.36%|
|3 Year Change||44.62%|
|5 Year Change||53.38%|
|Change since IPO||1,593.86%|
Recent News & Updates
Pfizer involvement in Zantac woes 'smaller than people think' - Wells Fargo
A decline in Pfizer's (NYSE:PFE) share price today is "unwarranted" as the company's exposure to litigation regarding the heartburn drug Zantac "may be smaller than people think," according to Wells Fargo. Analyst Mohit Bansal said "Overall, we think the weakness in PFE stock appears unwarranted as their liability may be minimal if any from our understanding." In April 2020, the U.S. FDA requested over-the-counter Zantac (ranitidine) and its generics be removed from the market after finding it is linked to unacceptable levels of the potential human carcinogen, N-nitrosodimethylamine. Drugmakers Sanofi (SNY), GlaxoSmithKline (GSK), and Haleon (HLN) are under pressure Thursday due to potential legal exposure.
|PFE||US Pharmaceuticals||US Market|
Return vs Industry: PFE exceeded the US Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: PFE exceeded the US Market which returned -11.7% over the past year.
|PFE Average Weekly Movement||3.7%|
|Pharmaceuticals Industry Average Movement||11.7%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: PFE is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PFE's weekly volatility (4%) has been stable over the past year.
About the Company
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.
Pfizer Inc. Fundamentals Summary
|PFE fundamental statistics|
Is PFE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PFE income statement (TTM)|
|Cost of Revenue||US$37.72b|
Last Reported Earnings
Jul 03, 2022
Next Earnings Date
|Earnings per share (EPS)||5.25|
|Net Profit Margin||29.11%|
How did PFE perform over the long term?See historical performance and comparison